Teva Pharmaceutical Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/22/2026)
| Balance Sheet | Total Assets | 40,749,000,000.00 | Equity Ratio | 19.41 % |
| Balance Sheet | Total Equity | 7,909,880,000.00 | ROA | 3.46 % |
| Cashflow | Capital Expenditures | -501,000,000.00 | P/FCF | 42.69 |
| Cashflow | Free Cash Flow | 1,148,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,649,000,000.00 | P/CF | 29.72 |
| Income | Earnings per Share (diluted) | 1.20 | Div. Yield | – |
| Income | Net Income | 1,410,000,000.00 | P/E | 34.82 |
| Income | Shares Outstanding | 1,173,000,000.00 | P/B | 6.20 |
| Income | Total Revenue | 17,258,000,000.00 | P/S | 2.84 |
Ratios calculated on: 11/5/2026
Company Description
Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva´s active pharmaceutical ingredient (API) business provides vertical integration to Teva´s own pharmaceutical production. The Company´s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.tevapharm.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more